PTCHF on OTC
American company
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Compare with Adamis Pharmaceuticals Corporation, SPRUCE BIOSCIENCES, INC. or InMed Pharmaceuticals Inc., or pick any stock.
See how the biggest companies compare on our leaderboards
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.3
From the company’s reports to the SEC. Every number links to the filing it came from.
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Contract revenue | $4.7M | $4.3M | $750.0K |
| Grant revenue | $0 | $513.0K | $2.6M |
| Total revenue | $4.7M | $4.8M | $3.3M |
| General and administrative expenses | -$46.6M | -$71.5M | -$53.3M |
| Research and development expenses | -$56.6M | -$69.5M | -$96.2M |
| Operating income/(loss) | -$98.5M | -$136.1M | -$146.2M |
| Gain/(loss) on deconsolidation of subsidiary | $0 | $151.8M | $61.8M |
| Gain/(loss) on investments held at fair value | $38.5M | -$2.4M | $77.9M |
| Realized gain/(loss) on sale of investments | $375.0K | $151.0K | -$122.0K |
| Gain/(loss) on investments in notes from associates | -$3.6M | $13.1M | -$27.6M |
| Other income/(expense) | $1.3M | $961.0K | -$908.0K |
| Other income/(expense) | $36.6M | $163.7M | $111.1M |
| Finance income | $13.0M | $22.7M | $16.0M |
| Finance costs contractual | -$1.9M | -$1.7M | -$3.4M |
| Finance income/(costs) fair value accounting | $0 | -$8.1M | $2.6M |
| Finance costs non-cash interest expense related to sale of future royalties | -$43.9M | -$8.1M | -$10.2M |
| Net finance income/(costs) | -$32.7M | $4.8M | $5.1M |
| Share of net income/(loss) of associates accounted for using the equity method | -$17.9M | -$8.8M | -$6.1M |
| Gain/(loss) on dilution of ownership interest in associates | $1.7M | $199.0K | $0 |
| Income/(loss) before taxes | -$110.9M | $23.8M | -$36.1M |
| Tax benefit/(expense) | $842.0K | $4.0M | -$30.5M |
| Income/(loss) for the year | -$110.1M | $27.8M | -$66.6M |
| Equity-accounted associates share of other comprehensive income/(loss) | $0 | $0 | $92.0K |
| Total other comprehensive income/(loss) | $0 | $0 | $92.0K |
| Total comprehensive income/(loss) for the year | -$110.1M | $27.8M | -$66.5M |
| Owners of the Group | -$109.7M | $53.5M | -$65.7M |
| Non-controlling interests | -$345.0K | -$25.7M | -$931.0K |
| Owners of the Group | -$109.7M | $53.5M | -$65.6M |
| Non-controlling interests | -$345.0K | -$25.7M | -$931.0K |
| Basic earnings/(loss) per share (in dollars per share) | -$0.46 | $0.21 | -$0.24 |
| Diluted earnings/(loss) per share (in dollars per share) | -$0.46 | $0.21 | -$0.24 |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Property and equipment, net | $5.2M | $7.1M | |
| Right of use asset, net | $6.3M | $8.1M | $9.8M |
| Intangible assets, net | $601.0K | $601.0K | |
| Investments held at fair value | $217.4M | $191.4M | $317.8M |
| Investment in associates equity method | $0 | $2.4M | $3.2M |
| Investment in notes from associates, non-current | $0 | $6.3M | |
| Other non-current assets | $165.0K | $475.0K | |
| Total non-current assets | $229.7M | $216.4M | |
| Trade and other receivables | $1.8M | $1.5M | |
| Income tax receivable | $6.4M | $0 | |
| Prepaid expenses | $6.6M | $4.4M | |
| Other financial assets | $1.6M | $1.6M | |
| Investment in notes from associates, current | $11.4M | $11.4M | |
| Short-term investments | $24.8M | $86.7M | |
| Cash and cash equivalents | $252.5M | $280.6M | $191.1M |
| Total current assets | $305.0M | $386.3M | |
| Total assets | $534.7M | $602.6M | |
| Share capital | $4.9M | $4.9M | |
| Share premium | $290.3M | $290.3M | |
| Treasury stock | -$41.2M | -$46.9M | |
| Merger reserve | $138.5M | $138.5M | |
| Translation reserve | $182.0K | $182.0K | |
| Other reserve | -$3.4M | -$4.7M | |
| Retained earnings/(Accumulated deficit) | -$77.2M | $32.5M | |
| Equity attributable to the owners of the Group | $312.1M | $414.7M | |
| Non-controlling interests | -$6.4M | -$6.8M | |
| Total equity | $305.7M | $407.9M | $458.2M |
| Sale of future royalties liability, non-current | $170.4M | $136.8M | |
| Lease liability, non-current | $11.1M | $14.7M | |
| Liability for share-based awards | $1.2M | $1.9M | |
| Total non-current liabilities | $182.7M | $153.3M | |
| Lease liability, current | $3.6M | $3.6M | |
| Trade and other payables | $23.2M | $27.0M | |
| Sale of future royalties liability, current | $13.2M | $6.4M | |
| Tax liability, current | $1.2M | $75.0K | |
| Notes payable | $4.9M | $4.1M | |
| Preferred share liability | $169.0K | $169.0K | |
| Total current liabilities | $46.3M | $41.4M | |
| Total liabilities | $229.0M | $194.7M | |
| Total equity and liabilities | $534.7M | $602.6M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Income/(loss) for the year | -$110.1M | $27.8M | -$66.6M |
| Depreciation and amortization | $3.3M | $3.6M | $4.9M |
| Share-based compensation expense | $8.2M | $22.9M | $4.4M |
| (Gain)/loss on investment held at fair value | -$38.5M | $2.4M | -$77.9M |
| Realized (gain)/loss on sale of investments | -$375.0K | -$151.0K | $265.0K |
| Gain on dilution of ownership interest in associates | -$1.7M | -$199.0K | $0 |
| Gain on deconsolidation of subsidiary | $0 | -$151.8M | -$61.8M |
| Share of net (gain)/loss of associates accounted for using the equity method | $17.9M | $8.8M | $6.1M |
| (Gain)/loss on investments in notes from associates | $3.6M | -$13.1M | $27.6M |
| (Gain)/loss on disposal of assets | -$93.0K | $14.0K | $318.0K |
| Impairment of fixed assets | $112.0K | $226.0K | $1.3M |
| Income taxes expense/(benefit) | -$842.0K | -$4.0M | $30.5M |
| Finance (income)/costs, net | $32.7M | -$4.8M | -$5.1M |
| Trade and other receivables | -$236.0K | $629.0K | $9.8M |
| Prepaid expenses and other financial assets | -$1.9M | -$1.3M | $2.8M |
| Deferred revenue | $0 | $0 | -$283.0K |
| Trade and other payables | -$1.0M | -$9.7M | $3.8M |
| Other | $0 | $92.0K | $1.4M |
| Income taxes paid | -$5.5M | -$37.9M | -$150.0K |
| Interest received | $13.6M | $23.5M | $14.5M |
| Interest paid | -$4.5M | -$1.3M | -$1.7M |
| Net cash provided by (used in) operating activities | -$85.1M | -$134.4M | -$105.9M |
| Purchase of property and equipment | -$6.0K | -$11.0K | -$70.0K |
| Proceeds from sale of property and equipment | $269.0K | $255.0K | $865.0K |
| Purchases of intangible assets | $0 | $0 | -$175.0K |
| Investment in preferred shares held at fair value | -$888.0K | -$14.4M | $0 |
| Sale of investments held at fair value | $2.8M | $298.1M | $33.3M |
| Investment in convertible notes from associates | -$150.0K | $0 | -$16.9M |
| Short-term note to associate | $0 | -$660.0K | $0 |
| Repayment of short-term note from associate | $0 | $660.0K | $0 |
| Cash derecognized upon loss of control over subsidiary | $0 | -$91.6M | -$13.8M |
| Purchases of short-term investments | -$84.0M | -$308.9M | -$178.9M |
| Proceeds from maturity of short-term investments | $145.3M | $357.4M | $244.6M |
| Other | $50.0K | $0 | $0 |
| Net cash provided by (used in) investing activities | $63.3M | $240.9M | $69.0M |
| Receipts from Royalty Purchase Agreement | $0 | $25.0M | $100.0M |
| Issuance of subsidiary preferred shares | $0 | $68.1M | $0 |
| Payment of lease liability | -$3.6M | -$3.4M | -$3.3M |
| Exercise of stock options | $106.0K | $895.0K | $1.2M |
| Repurchase of ordinary shares from Tender Offer, including associated costs | -$2.1M | -$102.8M | $0 |
| Payments of withholding taxes in connection with stock-based awards | -$801.0K | $0 | $0 |
| Purchase of treasury stock | $0 | -$4.8M | -$19.6M |
| Other | $0 | $0 | -$23.0K |
| Net cash provided by (used in) financing activities | -$6.3M | -$17.0M | $78.1M |
| Net increase (decrease) in cash and cash equivalents | -$28.2M | $89.6M | $41.2M |
| Purchase of intangible assets not yet paid in cash | $0 | $0 | $25.0K |
| Cost associated with Tender Offer not yet paid in cash | $0 | $2.1M | $0 |
| Settlement of restricted stock units through issuance of equity | $1.4M | $1.3M | $1.1M |
| Conversion of note receivable from associate into preferred shares | $2.8M | $0 | $0 |
Founded by Daphne Zohar.1
The company was founded by Daphne Zohar, an American entrepreneur, in 2005. It was the subject of an initial public offering on the London Stock Exchange in June 2015.
From Wikipedia’s article on PureTech Health, shared under CC BY-SA 4.0.5
Who has led PureTech Ventures, and when. Pick a name to see everywhere that person has worked.
Companies which PureTech Health founded include Karuna Pharmaceuticals, Gelesis, which has received FDA approval as a treatment for weight management, Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, and Follica which is developing new treatments for androgentic alopecia among others. PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics.
From Wikipedia’s article on PureTech Health, shared under CC BY-SA 4.0.5
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
The numbers on this page point here. Each one links to the record it came from.